Idiosyncratic liver injury: challenges and approaches

Area of Science:

• Hepatology
• Toxicology
• Genetics

Background:

• Drug-induced liver injury (DILI) presents a wide spectrum of liver disease manifestations.
• Idiosyncratic hepatocellular injury leading to acute liver failure is a rare but severe form of DILI, often resulting in labeling restrictions.
• This severe DILI form typically appears after weeks to months of drug treatment, characterized by high ALT levels and jaundice, indicating high mortality risk.

Discussion:

• Drugs causing severe DILI often induce frequent, minor aminotransferase elevations that may reverse, but the mechanisms of adaptation or progressive injury remain unclear.
• Preclinical models for severe idiosyncratic drug-induced liver toxicity are lacking, hindering understanding of the underlying mechanisms.
• Genetic and environmental factors likely contribute to individual susceptibility in DILI, necessitating focused phenotype/genotype studies.

Key Insights:

• Severe idiosyncratic hepatocellular DILI is a rare but critical concern, often linked to drugs causing minor, transient liver enzyme elevations in most patients.
• The lack of effective preclinical models and the rarity of severe events complicate research into DILI mechanisms.
• Understanding the genetic and environmental interplay is crucial for predicting and preventing severe DILI outcomes.

Outlook:

• The establishment of the Drug Induced Liver Injury Network (DILIN) by the NIH provides essential resources for studying DILI.
• Future research will focus on phenotype/genotype correlations in patients who survive severe DILI to uncover susceptibility factors.
• Developing better preclinical models and leveraging large-scale patient data are key to advancing DILI research and patient safety.